Quantitative benefit/risk assessment of the HPV vaccine for preventing anal cancer in males

Human Papillomaviruses (HPVs) are the primary pathogens causing anal cancers, accounting for nearly 90% of global cases. The HPV-associated anal cancers and deaths are worryingly increasing in men but can be prevented with the quadrivalent HPV (qHPV) vaccine. P95 estimated the benefit-risk balance of qHPV vaccine use in males, applying a multicriteria decision analysis (MCDA). The qHPV vaccine was shown to have a satisfactory BR balance in males, and MCDA is identified as a practical decision-making tool in evaluating the BR balance of vaccines.

You can read the published manuscript here: